INmune Bio (NASDAQ:INMB) Releases Quarterly Earnings Results, Beats Expectations By $0.16 EPS

Key Points

• INmune Bio beat earnings expectations: The company reported a quarterly loss of $0.05 per share, $0.16 better than analysts’ expected loss of $0.21.
• Pipeline progress remains central: Management expects to submit Ebstrocel’s U.K. marketing application by late Q3 or early Q4 2026, while XPro1595 received FDA Fast Track designation for early Alzheimer’s disease after positive Phase II biomarker results.
• Funding and valuation risks persist: INmune Bio had $18.4 million in cash at June 30, plus a subsequent $4.2 million Australian R&D rebate, with funds expected to last into Q2 2027; however, planned capital raises could dilute shareholders. The stock was recently rated a consensus “Moderate Buy,” despite some analyst downgrades to “Sell.”

INmune Bio (NASDAQ:INMB - Get Free Report) posted its quarterly earnings results on Thursday. The company reported ($0.05) earnings per share for the quarter, beating analysts' consensus estimates of ($0.21) by $0.16, Zacks reports.

Here are the key takeaways from INmune Bio's conference call:

• Positive Sentiment: INmune Bio expects to submit Ebstrocel’s U.K. marketing authorization application by the end of Q3 or early Q4 2026, followed by EMA and U.S. submissions in early 2027. MHRA alignment across clinical, non-clinical, and CMC requirements, plus approval of the pediatric investigation plan, reduces regulatory uncertainty.
• Positive Sentiment: Ebstrocel manufacturing and supply-chain readiness advanced, including commercial-ready cord-tissue processing, transfer of MSC isolation to the intended commercial facility, and expanded access to umbilical cord tissue through Anthony Nolan. Management believes this supports scalable supply for potential U.K., European, and U.S. commercialization.
• Positive Sentiment: XPro received FDA Fast Track designation for early Alzheimer’s disease, while the MINDFuL Phase II study showed statistically significant improvement in white-matter myelin MRI biomarkers. Management is advancing a registrational strategy and evaluating partnerships, although Alzheimer’s remains the clinical priority.
• Neutral Sentiment: The company reported $18.4 million in cash at June 30 and received a subsequent $4.2 million Australian R&D rebate, with funding expected to last into Q2 2027. Management estimates a forward burn rate of roughly $1 million to $1.5 million per month and expects to raise capital selectively, but future financing could still create dilution.
• Positive Sentiment: If approved, management estimates a U.K. opportunity of roughly 800 RDEB patients and anticipates pricing of approximately £400,000–£500,000 per child annually, subject to reimbursement negotiations. The company also highlighted a potential U.S. rare pediatric disease priority review voucher, which it estimates could be worth $100 million to $200 million, though neither approval nor monetization is assured.

INmune Bio Price Performance

NASDAQ INMB traded up $0.01 during mid-day trading on Thursday, hitting $1.91. The company's stock had a trading volume of 233,316 shares, compared to its average volume of 546,470. The firm has a market capitalization of $50.78 million, a P/E ratio of -1.14 and a beta of 0.97. INmune Bio has a 52-week low of $1.09 and a 52-week high of $2.85. The stock's fifty day simple moving average is $1.61 and its two-hundred day simple moving average is $1.47.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of INMB. Virtu Financial LLC acquired a new stake in shares of INmune Bio during the 4th quarter valued at approximately $32,000. XTX Topco Ltd grew its stake in shares of INmune Bio by 41.3% in the 4th quarter. XTX Topco Ltd now owns 68,865 shares of the company's stock worth $107,000 after purchasing an additional 20,121 shares during the last quarter. Quadrature Capital Ltd bought a new stake in shares of INmune Bio in the 4th quarter worth approximately $26,000. Jain Global LLC acquired a new stake in INmune Bio during the fourth quarter valued at approximately $66,000. Finally, Charles Schwab Investment Management Inc. lifted its stake in INmune Bio by 20.1% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 50,252 shares of the company's stock valued at $78,000 after purchasing an additional 8,427 shares during the last quarter. Institutional investors and hedge funds own 12.72% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on INMB shares. Weiss Ratings downgraded INmune Bio from a "sell (d-)" rating to a "sell (e+)" rating in a report on Wednesday. Wall Street Zen downgraded shares of INmune Bio from a "hold" rating to a "sell" rating in a report on Saturday, July 25th. One equities research analyst has rated the stock with a Strong Buy rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy".

About INmune Bio

INmune Bio, Inc is a clinical-stage immunology company based in San Diego, California, focused on harnessing the innate immune system to combat a range of serious diseases. The company's research and development efforts concentrate on modulating cellular pathways to restore and enhance the body's natural defenses, particularly in oncology and neurodegenerative conditions.

The company's lead therapeutic candidate, XPro1595 (also referred to as INB03), is a proprietary selective inhibitor of soluble tumor necrosis factor (TNF) designed to reduce chronic inflammation without impairing membrane-bound TNF functions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source